Feed NVZMF
NV

Novozymes A/S

NVZMF · OTC

$65.11 +2.86% (+$1.81)
1M -8.45%
Market Cap 27.0B €
P/E Ratio 42.78x
Div. Yield 1.57%
ROE 5.78%

Bulios Fair Price

$58.38

10.3% downside

Current Price

$65.11

Undervalued Fair Value Overvalued

According to Bulios Fair Price, NVZMF is currently overvalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Analysis

An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.

Piotroski F-Score Strong
7/9
Valuation
17 /100
Expensive
P/FCF 49.36x
P/E 42.78x
P/B 2.43x
Growth
1 /100
Declining
FCF growth 12.38%
EPS growth 54.41%
Book val. growth 7.77%
Profitability
100 /100
Strong
Op. margin 20.98%
Gross margin 54.85%
FCF margin 12.74%
Quality
44 /100
Average
ROA 3.81%
ROIC 6.24%
Asset turnover 0.26x
Debt
90 /100
Low
Int. coverage 22.09x
Debt/Equity 0.28x
Net debt/EBITDA 1.91x
Stability
43 /100
Moderate
EPS volatility 90.56%
Beta 0.62x
Profitable years 6

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about NVZMF
Online

Sector

Basic Materials

Industry

Chemicals - Specialty

CEO

Ester Baiget

Employees

11,641

Headquarters

Lyngby

Upcoming events

05 NOV

Earnings

Upcoming earnings report

34d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.